Arcturus slips as Goldman Sachs hands two downgrades in quick succession
naphtalina/iStock via Getty Images
- The shares of Arcturus Therapeutics (NASDAQ:ARCT) have come under pressure in the pre-market with a loss of ~6.4%
after Goldman Sachs downgraded the stock for the second time within 24 hours. - “Recent rally on next-generation…
